Access to essential drugs in poor countries: a lost battle?
about
Pre-admission antibiotics for suspected cases of meningococcal diseasePre-admission antibiotics for suspected cases of meningococcal diseaseA breakthrough in R&D; for neglected diseases: new ways to get the drugs we needSubstandard/counterfeit antimicrobial drugsUse of Aptamers as Diagnostics Tools and Antiviral Agents for Human VirusesLifestyle drugs: issues for debatePolicy statements adopted by the Governing Council of the American Public Health Association, November 15, 2000Overdependence on For-Profit Pharmacies: A Descriptive Survey of User Evaluation of Medicines Availability in Public Hospitals in Selected Nigerian StatesEMERGING AND TRANSITIONING COUNTRIES' ROLE IN GLOBAL HEALTH.The politics of medicine and the global governance of pandemic influenza.How do intellectual property law and international trade agreements affect access to antiretroviral therapy?A student-led campaign to help tackle neglected tropical diseases.Market failure and the poverty of new drugs in maternal healthWR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled studyResearch ethics review in humanitarian contexts: the experience of the independent ethics review board of Médecins Sans FrontièresAchieving a dream: meeting policy goals related to improving drug accessIn vivo effect of Commiphora swynnertonii ethanolic extracts on Trypanosoma congolense and selected immunological components in miceThe cost to global health of drug company profits.Technology transfer: the problem with "trickle down" theory.Synthesis and antileishmanial activities of novel 3-substituted quinolines.Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamstersRe-emergence of epidemic sleeping sickness in southern Sudan.Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnershipsDrugs for neglected diseases: a failure of the market and a public health failure?In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species.Design and synthesis of novel antileishmanial compounds.Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry prioritiesUtilisation of obstetric sonography at a peri-urban health centre in Uganda.Civil conflict and sleeping sickness in Africa in general and Uganda in particular.Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessmentHuman African trypanosomiasis: pharmacological re-engagement with a neglected disease.An ethics-based approach to global child health researchGlobal Health Governance at a Crossroads.Big hopes for the children of the world: a review of the Millennium Development Goals.Recent initiatives and strategies to developing new drugs for tropical parasitic diseases.The ethics of intellectual property rights in an era of globalization.Neglected tropical disease and emerging infectious disease: an analysis of the history, promise and constraints of two worldviews.Pre-admission antibiotics for suspected cases of meningococcal disease.Introductory note: The access to Essential Medicines Campaign.
P2860
Q24200590-D1A74E97-512D-44F2-B209-B6D08BC0EFFEQ24242705-AE11993D-1DD5-4E8B-80A2-4D45AE2D2280Q24810470-27A53685-8859-4624-88D2-7E3EACDEC733Q27009319-F24685A9-64FB-48BF-A103-88DF05DB72E6Q28079654-FE4DF02F-210E-4D55-81D0-35CDB970704CQ28366184-2D64CBEA-D29D-4F95-89E5-4E18D9BC290BQ28388315-9CDB3AF3-487A-4C73-8599-F202D1B328D6Q28553191-A0FBD18D-825C-40B4-B507-97DCB0453D68Q30390577-CB473A43-1AD4-477F-9A9C-B538684C241BQ30428703-132AF9A5-2375-4DF4-B085-6B5C9D004129Q33252472-19591AA1-F85D-439D-AC7C-801A52246AC0Q33293148-452AB387-3244-428A-8EF7-CC11859D0FBDQ33316160-65620ACA-94D1-4240-921D-87E7DFE510E6Q33438898-65D96DBB-3E78-40F0-AF39-4C44FEA02514Q33487659-96717188-9DE7-4145-9CAD-09F89A5C3B8EQ33643770-68324447-95CF-4413-9FD6-F6C223BADF4FQ33722744-DCBCD335-65D7-4AAB-9DCB-47698F845DA5Q33728848-04B5400D-CAAF-4AD1-B17B-DEEDF37646A8Q33821457-72992BBF-95AF-4F86-ABC2-7709C0C8E19FQ33857721-48FC0CBD-5EC4-4D55-B815-C10EC383C48CQ33879398-877C649F-61D9-4D97-82B7-5804792742A2Q34141596-E142284C-39F0-450E-A7B4-7D44C244C951Q34248743-3EA388EF-6607-44B0-B172-A88D0E7729C7Q34250696-E2ED05BA-EFE1-4820-9F35-C3A6A2240E60Q34434847-C3507B02-2656-4113-AAF9-846480EEF5DFQ35006918-48D434F6-C399-479E-8EFD-602B9A0DBDCFQ35061244-AA5CD707-96A1-4518-9A3E-63525D1C1E4CQ35102367-B9A35B5D-8AA6-4924-A847-0BC414482799Q35211828-06DA68AC-F28F-4C51-9FF4-DE1527E2E174Q35750445-DF761F1F-BF8C-4E94-BAC2-5D52F4F5575AQ36603392-AC29D8FC-B336-4381-953D-6D32FC648549Q36740553-29822B79-7FD4-4A16-A3A4-4A5EBE22993AQ37469037-3852A003-1895-44FC-A81A-43C59C25EF5BQ37697990-1370E59D-D0C3-4E92-9466-7BD265E6882AQ37951263-5340FA28-5A3D-47CF-9A73-040BBFAE3791Q38088306-64E17A84-E3B8-40DC-BD7A-504B01A7408AQ38180466-D133E126-5D09-4568-A3D7-6338D75C8938Q38237279-12C00BF9-7E0A-4916-A251-8E97152F7F54Q38726046-BDBBA62B-8B41-4D6D-8EA5-E4CABBD3D0F4Q39137778-65614E1C-CFB5-457B-A7C3-7821F691F052
P2860
Access to essential drugs in poor countries: a lost battle?
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Access to essential drugs in poor countries: a lost battle?
@en
Access to essential drugs in poor countries: a lost battle?
@nl
type
label
Access to essential drugs in poor countries: a lost battle?
@en
Access to essential drugs in poor countries: a lost battle?
@nl
prefLabel
Access to essential drugs in poor countries: a lost battle?
@en
Access to essential drugs in poor countries: a lost battle?
@nl
P2093
P356
P1476
Access to essential drugs in poor countries: a lost battle?
@en
P2093
P304
P356
10.1001/JAMA.281.4.361
P407
P577
1999-01-01T00:00:00Z